These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16194268)

  • 21. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial.
    Afshar H; Roohafza H; Mousavi G; Golchin S; Toghianifar N; Sadeghi M; Talaei M
    J Psychopharmacol; 2009 Mar; 23(2):157-62. PubMed ID: 18515465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.
    Advokat C; Dixon D; Schneider J; Comaty JE
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):487-95. PubMed ID: 15093956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
    Strassnig M; Miewald J; Keshavan M; Ganguli R
    Schizophr Res; 2007 Jul; 93(1-3):90-8. PubMed ID: 17478082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topiramate-induced weight loss in schizophrenia: a retrospective case series study.
    Lévy E; Agbokou C; Ferreri F; Chouinard G; Margolese HC
    Can J Clin Pharmacol; 2007; 14(2):e234-9. PubMed ID: 17565171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
    Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
    Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of atypical antipsychotics in the treatment of schizophrenia.
    Jessen LM
    Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
    [No Abstract]   [Full Text] [Related]  

  • 28. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.
    Garyfallos G; Dimelis D; Kouniakis P; Sidiropoulos N; Karastergiou A; Lavrentiadis G; Giouzepas J; Fokas K
    Eur Psychiatry; 2003 Oct; 18(6):320-1. PubMed ID: 14611929
    [No Abstract]   [Full Text] [Related]  

  • 30. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bodyweight gain with atypical antipsychotics. A comparative review.
    Wetterling T
    Drug Saf; 2001 Jan; 24(1):59-73. PubMed ID: 11219487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
    McElroy SL; Frye MA; Altshuler LL; Suppes T; Hellemann G; Black D; Mintz J; Kupka R; Nolen W; Leverich GS; Denicoff KD; Post RM; Keck PE
    Bipolar Disord; 2007 Jun; 9(4):426-34. PubMed ID: 17547588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.
    Kim JH; Yim SJ; Nam JH
    Schizophr Res; 2006 Feb; 82(1):115-7. PubMed ID: 16326074
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topiramate leukopenia on clozapine.
    Behar D; Schaller JL
    Eur Child Adolesc Psychiatry; 2004 Feb; 13(1):51-2. PubMed ID: 14991432
    [No Abstract]   [Full Text] [Related]  

  • 37. Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?
    Archie SM; Goldberg JO; Akhtar-Danesh N; Landeen J; McColl L; McNiven J
    Psychiatr Serv; 2007 Feb; 58(2):233-9. PubMed ID: 17287381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotic drug side effect issues in bipolar manic patients.
    Zarate CA
    J Clin Psychiatry; 2000; 61 Suppl 8():52-61; discussion 62-3. PubMed ID: 10811244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
    Vieweg WV; Sood AB; Pandurangi A; Silverman JJ
    Acta Psychiatr Scand; 2005 Mar; 111(3):177-84. PubMed ID: 15701101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.